TY - JOUR
T1 - Pharmacological characterization of linear analogues of vasopressin generated by the systematic substitution of positions 1 and 6 by l-amino acids
AU - Howl, John
AU - Filer, Andrew D.J.
AU - Parslow, Rosemary A.
AU - Kirk, Christopher J.
AU - Jurzak, Mirek
AU - Smith, A. Ian
AU - Wheatley, Mark
PY - 1994/4/29
Y1 - 1994/4/29
N2 - Eighteen linear analogues of [Arg8]vasopressin (AVP) were synthesized by systematically substituting the cysteine residues at positions 1 and 6 with a range of l-amino acids. Screening by competition ligand binding revealed that the combinations of amino acids residues tolerated at these positions was very restricted with respect to retention of vasopressin receptor (VPR) binding. Consequently, only three of the eighteen analogues investigated, [Pro1,Met6]AVP, [Gly1,Met6]AVP and [Phe1,Lys6]AVP, bound to the V1a receptor. Furthermore, these three peptides were all selective for the V1a receptor rather than the V1b, V2 and vasotocin receptors. In addition, although very homolous to the natural agonist, these analogues were in fact antagonists at V1a receptors. These data provide insights into the biophysical requirements at positions 1 and 6 of linear ligands for binding to V1a receptors and furthermore, supply clues to the nature of the receptor:ligand interaction.
AB - Eighteen linear analogues of [Arg8]vasopressin (AVP) were synthesized by systematically substituting the cysteine residues at positions 1 and 6 with a range of l-amino acids. Screening by competition ligand binding revealed that the combinations of amino acids residues tolerated at these positions was very restricted with respect to retention of vasopressin receptor (VPR) binding. Consequently, only three of the eighteen analogues investigated, [Pro1,Met6]AVP, [Gly1,Met6]AVP and [Phe1,Lys6]AVP, bound to the V1a receptor. Furthermore, these three peptides were all selective for the V1a receptor rather than the V1b, V2 and vasotocin receptors. In addition, although very homolous to the natural agonist, these analogues were in fact antagonists at V1a receptors. These data provide insights into the biophysical requirements at positions 1 and 6 of linear ligands for binding to V1a receptors and furthermore, supply clues to the nature of the receptor:ligand interaction.
KW - ligand
KW - oxytocin
KW - peptide
KW - receptor
KW - subtypes
KW - vasotocin
UR - http://www.scopus.com/inward/record.url?scp=0028277989&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(94)90523-1
DO - 10.1016/0006-2952(94)90523-1
M3 - Article
C2 - 8185660
AN - SCOPUS:0028277989
SN - 0006-2952
VL - 47
SP - 1497
EP - 1501
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 9
ER -